Shanghai Serum Bio-Technology Hits Day Low at CNY 32.24 Amid Price Pressure

Shanghai Serum Bio-Technology Co., Ltd. experienced significant volatility on July 17, 2026, with the stock declining by 15.52% and reaching an intraday low of CNY 32.24. This performance starkly contrasts with the broader market, as the China Shanghai Composite index fell by only 3.05% on the same day. Over the past week, Shanghai Serum's stock has dropped 15.85%, and its monthly performance shows a decline of 31.52%. Despite these short-term challenges, the company has demonstrated a notable annual return of 54.23%, outperforming the China Shanghai Composite's 7.03% gain over the same period. Key financial metrics indicate areas of concern, including a low Return on Capital Employed (ROCE) of 16.43% and a Return on Equity (ROE) of 4.25%. The company's net sales growth has been modest at an annual rate of 1.64% over the last five years, while operating profit has increased by 5.83%. Additionally, the debt-equity ratio stands at -0.69, reflecting a challenging financial structure. As a small-cap player in the pharmaceuticals and biotechnology sector, Shanghai Serum continues to navigate a complex market landscape.